Chong Xian Pan, MD, PhD, Harvard Medical School, Boston, MA, discusses the synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. The PI3K pathway is frequently altered in bladder cancer, however, there is currently no approved targeted therapy for PI3K in bladder cancer. Immunotherapy has response rates of 20-25% in bladder cancer, however, preclinical studies have demonstrated PI3K inhibitors can potentiate immunotherapy. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.